1. Inicio
  2. Publicaciones
  3. Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Balaguer, A

Grupos

Abstract

Alzheimer's disease (AD) is the most prevalent dementia, but it shows similar initial symptoms to other neurocognitive diseases (Lewy body disease (LBD) and frontotemporal dementia (FTD)). Thus, the identification of reliable AD plasma biomarkers is required. The aim of this work is to evaluate the use of a few plasma biomarkers to develop an early and specific AD screening method. Plasma p-Tau181, neurofilament light (NfL), and glial fibrillary acid protein (GFAP) were determined by Single Molecule Assay (SIMOA & REG; Quanterix, Billerica, MA, USA) in patients with mild cognitive impairment due to AD (MCI-AD, n = 50), AD dementia (n = 10), FTD (n = 20), LBD (n = 5), and subjective cognitive impairment (SCI (n = 21)). Plasma p-Tau181 and GFAP showed the highest levels in AD dementia, and significant correlations with clinical AD characteristics; meanwhile, NfL showed the highest levels in FTD, but no significant correlations with AD. The partial least squares (PLS) diagnosis model developed between the AD and SCI groups showed good accuracy with a receiver operating characteristic (ROC) area under curve (AUC) of 0.935 (CI 95% 0.87-0.98), sensitivity of 86%, and specificity of 88%. In a first screen, NfL plasma levels could identify FTD patients among subjects with cognitive impairment. Then, the developed PLS model including p-Tau181 and GFAP levels could identify AD patients, constituting a simple, early, and specific diagnosis approach.

Datos de la publicación

ISSN/ISSNe:
1661-6596, 1422-0067

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES  MDPI

Tipo:
Article
Páginas:
-
PubMed:
37762457
Factor de Impacto:
1,176 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 7

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Alzheimer's disease; frontotemporal dementia; plasma; biomarker; SIMOA; diagnosis

Proyectos y Estudios Clínicos

Identificación de biomarcadores presintomáticos y mínimamente invasivos de la enfermedad de alzheimer: peroxidación lipídica, e integración lipidómica-epigenómica.

Investigador Principal: MARÍA CONSUELO CHÁFER PERICÁS

PI19/00570 . INSTITUTO DE SALUD CARLOS III . 2020

Contratos Miguel Servet II 2021. Consuelo Cháfer.

Investigador Principal: MARÍA CONSUELO CHÁFER PERICÁS

CPII21/00006 . INSTITUTO DE SALUD CARLOS III . 2022

Diagnóstico y pronóstico de la Enfermedad de Alzheimer asintomática y sintomática temprana: metilómica del ADN y proteómica.

Investigador Principal: MARÍA CONSUELO CHÁFER PERICÁS

PI22/00594 . INSTITUTO DE SALUD CARLOS III . 2023

Compartir